BR112023021108A2 - Derivados de 2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-imidazol como ativadores do receptor de glp1 para o tratamento de obesidade - Google Patents

Derivados de 2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-imidazol como ativadores do receptor de glp1 para o tratamento de obesidade

Info

Publication number
BR112023021108A2
BR112023021108A2 BR112023021108A BR112023021108A BR112023021108A2 BR 112023021108 A2 BR112023021108 A2 BR 112023021108A2 BR 112023021108 A BR112023021108 A BR 112023021108A BR 112023021108 A BR112023021108 A BR 112023021108A BR 112023021108 A2 BR112023021108 A2 BR 112023021108A2
Authority
BR
Brazil
Prior art keywords
methyl
methylbenzo
oxetan
dioxol
piperidin
Prior art date
Application number
BR112023021108A
Other languages
English (en)
Inventor
Chun Zhang
Chung-Yeh Wu
Daniel Smith
Lara Czabaniuk
Liansheng Su
Lihua Yang
Martin Allan
Matthew Carson
Ming Qian
Ping Zhang
Thomas Caya
Troy Smith
Xilin Zhou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/IB2022/053367 external-priority patent/WO2022219495A1/en
Publication of BR112023021108A2 publication Critical patent/BR112023021108A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados de 2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1- il)metil)-1-(((s)-oxetan-2-il)metil)-1h-imidazol como ativadores do receptor de glp1 para o tratamento de obesidade. a presente invenção refere-se a compostos da fórmula (i) (i), como ativadores do receptor de peptídeo semelhante a glucagon 1 (glp1) para o tratamento de obesidade, diabetes mellitus tipo 2, resistência à insulina, hiperinsulinemia, intolerância à glicose, hiperglicemia, uma ou mais complicações diabéticas, nefropatia diabética, dislipidemia, doença hepática gordurosa não alcoólica (nafld), esteato-hepatite não alcoólica (nash), hipertensão, aterosclerose, doença arterial periférica, acidente vascular cerebral, cardiomiopatia, fibrilação atrial, insuficiência cardíaca, doença cardíaca coronariana e neuropatia. os compostos preferenciais são, por exemplo, derivados de 2-((4-((s)-2-(4-cloro-2-fluorofenil) -2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)- oxetan-2-il)metil)-1h-imidazol e compostos similares, como, por exemplo, c-1, c-2, c-3, c-4 e outros compostos.
BR112023021108A 2021-04-12 2022-04-11 Derivados de 2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-imidazol como ativadores do receptor de glp1 para o tratamento de obesidade BR112023021108A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163173592P 2021-04-12 2021-04-12
US202263308843P 2022-02-10 2022-02-10
US202263323401P 2022-03-24 2022-03-24
PCT/IB2022/053367 WO2022219495A1 (en) 2021-04-12 2022-04-11 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity

Publications (1)

Publication Number Publication Date
BR112023021108A2 true BR112023021108A2 (pt) 2023-12-12

Family

ID=88309140

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021108A BR112023021108A2 (pt) 2021-04-12 2022-04-11 Derivados de 2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-imidazol como ativadores do receptor de glp1 para o tratamento de obesidade

Country Status (9)

Country Link
US (1) US20240182456A1 (pt)
EP (1) EP4323354A1 (pt)
JP (1) JP2024514826A (pt)
KR (1) KR20230170034A (pt)
AU (1) AU2022259044A1 (pt)
BR (1) BR112023021108A2 (pt)
CA (1) CA3215916A1 (pt)
IL (1) IL307590A (pt)
MX (1) MX2023011977A (pt)

Also Published As

Publication number Publication date
US20240182456A1 (en) 2024-06-06
JP2024514826A (ja) 2024-04-03
EP4323354A1 (en) 2024-02-21
KR20230170034A (ko) 2023-12-18
CA3215916A1 (en) 2022-10-20
MX2023011977A (es) 2023-10-23
AU2022259044A1 (en) 2023-10-19
IL307590A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
CL2023003038A1 (es) Derivados de benzo[d][1,3]dioxol como activadores del receptor glp1 para tratamiento de obesidad
JP2015187141A5 (pt)
BR112022005461A2 (pt) Composto de glp-1
RU2345067C2 (ru) Ингибиторы дпп-iv
HRP20120029T1 (hr) Derivati (4(4-[6-trifluorometil-piridin-3-ilamino)-n-sadržavajući-heteroaril]-fenil)-cikloheksil)-octene kiseline i njihove farmaceutske uporabe
NO20056056L (no) N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer
RU2430101C2 (ru) Ингибиторы белок-тирозин-фосфатазы человека и способы применения
RU2006140795A (ru) Ингибиторы дпп-iv
Wu et al. Synthesis and biological evaluation of novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase inhibitors
EA018894B1 (ru) N,n-диметил-5-(2-метил-6-((5-метилпиразин-2-ил)карбамоил)бензо-фуран-4-илокси)пиримидин-2-карбоксамид, используемый в качестве активатора глюкокиназы, и содержащая его фармацев-тическая композиция
TN2016000558A1 (en) Fatty acids and their use in conjugation to biomolecules
Yanagisawa et al. Novel oximes having 5-benzyl-2, 4-thiazolidinedione as antihyperglycemic agents: synthesis and structure–activity relationship
RU2009127781A (ru) Производные аденозина в качестве частичных и полных агонистов а1 аденозиновых рецепторов
JP5538528B2 (ja) 新規なｇｐｒ１１９アゴニスト
CA2448741A1 (en) Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
JPWO2021160127A5 (pt)
RU2013142011A (ru) З-аминопиридины в качестве агонистов gpbar1
BR112023021108A2 (pt) Derivados de 2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-imidazol como ativadores do receptor de glp1 para o tratamento de obesidade
Fredholm et al. Inotropic and lusitropic effects of levosimendan and milrinone assessed by strain echocardiography—A randomised trial
JPWO2022028572A5 (pt)
AU596616B2 (en) Cardiotonic thiazolones
BRPI0409501A (pt) compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças
Oyama et al. Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study
JP2019535791A5 (pt)
Lohray et al. Novel pyrrole-containing hypoglycemic and hypotriglyceridemic compounds